Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing

Circulation. 2007 Apr 10;115(14):1948-67. doi: 10.1161/CIRCULATIONAHA.107.181946. Epub 2007 Mar 21.

Abstract

Despite compliance with lifestyle recommendations, some children and adolescents with high-risk hyperlipidemia will require lipid-lowering drug therapy, particularly those with familial hypercholesterolemia. The purpose of this statement is to examine new evidence on the association of lipid abnormalities with early atherosclerosis, discuss challenges with previous guidelines, and highlight results of clinical trials with statin therapy in children and adolescents with familial hypercholesterolemia or severe hypercholesterolemia. Recommendations are provided to guide decision-making with regard to patient selection, initiation, monitoring, and maintenance of drug therapy.

Publication types

  • Practice Guideline

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Age of Onset
  • Anticholesteremic Agents / classification
  • Anticholesteremic Agents / therapeutic use
  • Arteriosclerosis / diagnostic imaging
  • Arteriosclerosis / epidemiology
  • Arteriosclerosis / etiology
  • Arteriosclerosis / pathology
  • Arteriosclerosis / prevention & control*
  • Child
  • Child, Preschool
  • Cholesterol, Dietary
  • Cholesterol, LDL / blood
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Contraindications
  • Diabetes Complications / epidemiology
  • Diet, Fat-Restricted
  • Dietary Fats
  • Disease Progression
  • Dyslipidemias / complications
  • Dyslipidemias / diagnosis
  • Dyslipidemias / diet therapy
  • Dyslipidemias / drug therapy*
  • Exercise Therapy
  • Female
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / adverse effects
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemia Type II / complications
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / diet therapy
  • Hyperlipoproteinemia Type II / drug therapy
  • Hyperlipoproteinemia Type II / epidemiology
  • Hyperlipoproteinemias / classification
  • Hyperlipoproteinemias / drug therapy
  • Hyperlipoproteinemias / epidemiology
  • Hyperlipoproteinemias / genetics
  • Hypolipidemic Agents / administration & dosage
  • Hypolipidemic Agents / adverse effects
  • Hypolipidemic Agents / therapeutic use*
  • Infant
  • Male
  • Metabolic Syndrome / epidemiology
  • Middle Aged
  • Obesity / epidemiology
  • Phytotherapy
  • Risk Factors
  • Ultrasonography

Substances

  • Anticholesteremic Agents
  • Cholesterol, Dietary
  • Cholesterol, LDL
  • Dietary Fats
  • HIV Protease Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents